This newsletter presents you the following key sessions:
1. Video-interview with D. Verhoeven, medical oncologist, AZ KLINA, Belgium on: The advances in
personalizing the treatment of women with advanced ovarian cancer
2. Regorafenib improves survival in patients with metastatic CRC progressing after standard therapy,
especially in those without prior targeted therapies
3. Abiraterone acetate significantly prolongs survival in patients with chemotherapy-naïve metastatic
castration-resistant prostate cancer
4. Head-to-head Phase III trial demonstrates superior progression-free survival for afatinib compared
to erlotinib in patients with advanced squamous cell carcinoma of the lung
5. Breast cancer treatment with everolimus and exemestane for ER-positive women: the 2nd interim
analysis of the BRAWO trial
6. Nivolumab shows signs of superior response rate compared to standard chemotherapy in advanced
melanoma